Associations between serum levels of C3, C4, and total classical complement activity in COVID-19 patients at the time of admission and clinical outcome
- Authors: Razi A.1, Azimian A.1, Arezumand R.1, Solati A.1, Ahmadabad H.N.1
-
Affiliations:
- North Khorasan University of Medical Sciences
- Issue: Vol 12, No 5 (2022)
- Pages: 869-874
- Section: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/2220-7619/article/view/119122
- DOI: https://doi.org/10.15789/2220-7619-ABS-1925
- ID: 119122
Cite item
Full Text
Abstract
In the present study, we investigated the association between complement system status at the time of admission and clinical outcomes in COVID-19 patients. This single-center study was carried out with sixty-one adult patients with COVID-19 who were hospitalized at Imam Hassan Hospital of North Khorasan University of Medical Sciences (Bojnurd, Iran) with less than three days passage since onset of COVID-19 symptoms. Twenty-three healthy volunteers with demographic features similar to the patient group (matched by age and gender) were included in the study as a control group. Patient information including demographic information, demographic data, clinical characteristics, and clinical outcomes were obtained from electronic medical records. Of 61 hospitalized patients with COVID-19, 28 (47.54%) were female, and the average age was 48.7±8.8 years. The healthy control group included 23 cases (11 (47.8%) female, 12 (52.1%) males, mean age 46.4±4.4 years). Twenty-one of the 61 patients (34.4%) were admitted to the ICU, and sixteen of them (26.2%) died. Thirty-three (54.10%) patients with COVID-19 were hospitalized for less than 7 days, and 28 (45.90%) of them were hospitalized for ≥ 7 days. Our results show that length of hospital stay in the no-ICU group was significantly lower than the ICU admission or death groups (6.49±0.24 vs. 8.85±1.59 and 10.53±1.80, p = 0.0002). The levels of C3, C4, and CH50 were determined through the immunoturbidimetric method and single-radial-haemolysis plates, respectively, on serum samples obtained from patients at the time of admission or those in the control group. Our results indicate that C3, C4 and CH50 levels were markedly lower in COVID-19 patients than in the control group. We also found that complement parameter levels in COVID-19 patients who died or were admitted to ICU were significantly lower than in non-ICU COVID-19 patients. In general, it seems that serum level of C3, C4, and CH50 at admission may predict disease progression or adverse clinical outcome in COVID-19 patients.
Full Text
##article.viewOnOriginalSite##About the authors
A. Razi
North Khorasan University of Medical Sciences
Email: raknv@mail.ru
PhD, MD (Medicine), Assistant Professor
Iran, Islamic Republic of, BojnurdA. Azimian
North Khorasan University of Medical Sciences
Email: raknv@mail.ru
PhD, MD (Medicine), Associate Professor, Faculty Member, Department of Pathobiology and Laboratory Sciences
BojnurdR. Arezumand
North Khorasan University of Medical Sciences
Email: raknv@mail.ru
PhD, MD (Medicine), Assistant Professor, Faculty Member, Department of Pathobiology and Laboratory Sciences
Iran, Islamic Republic of, BojnurdA. Solati
North Khorasan University of Medical Sciences
Email: raknv@mail.ru
PhD, MD (Philosophy), Associate Professor, Faculty Member, Department of English Language
Iran, Islamic Republic of, BojnurdH. N. Ahmadabad
North Khorasan University of Medical Sciences
Author for correspondence.
Email: namdar360@gmail.com
PhD, MD (Medicine), Associate Professor, Faculty Member, Department of Pathobiology and Laboratory Sciences
Iran, Islamic Republic of, BojnurdReferences
- Agrawal P., Nawadkar R., Ojha H., Kumar J., Sahu A. Complement evasion strategies of viruses: an overview. Front. Microbiol., 2017, vol. 8, pp. 1117. doi: 10.3389/fmicb.2017.01117
- Baric R.S. Emergence of a highly fit SARS-CoV-2 variant. N. Engl. J. Med., 2020, vol. 383, no. 27, pp. 2684–2686. doi: 10.1056/NEJMcibr2032888
- Bjornson A.B., Mellencamp M.A., Schiff G.M. Complement is activated in the upper respiratory tract during influenza virus infection. Am. Rev. Respir. Dis., 1991, vol. 143, no. 5, pp. 1062–1066. doi: 10.1164/ajrccm/143.5_Pt_1.1062
- Bosmann M., Ward P.A. Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. In: Current Topics in Innate Immunity I.I. Advances in Experimental Medicine and Biology, vol. 946. Eds.: J. Lambris, G. Hajishengallis. New York: Springer, 2012, vol. 946, pp. 147–159. doi: 10.1007/978-1-4614-0106-3_9
- Dheir H., Sipahi S., Yaylaci S., Köroğlu M., Erdem A.F., Karabay O. Is there relationship between SARS-CoV-2 and the complement C3 and C4? Turk. J. Med. Sci., 2020, vol. 50, no. 4, pp. 687–688. doi: 10.3906/sag-2004-336
- Fang S., Wang H., Lu L., Jia Y., Xia Z. Decreased complement C3 levels are associated with poor prognosis in patients with COVID-19: a retrospective cohort study. Int. Immunopharmacol., 2020, vol. 89 (Pt A): 10707. doi: 10.1016/j.intimp.2020.107070
- Fletcher-Sandersjöö A., Bellander B.-M. Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review. Thromb. Res., 2020, vol. 194, pp. 36–41. doi: 10.1016/j.thromres.2020.06.027
- Ghazavi A., Mosayebi G., Keshavarzian N., Rabiemajd S., Ganji A. Reduction of inflammatory C3 and C4 complement proteins in severe COVID-19 patients. Preprint (Version 1) available at Research Square. 2020. 13 p. doi: 10.21203/rs.3.rs-127493/v1
- Gibson P.G., Qin L., Puah S.H. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. Med. J. Aust., 2020, vol. 213, no. 2, pp. 54–56. doi: 10.5694/mja2.50674
- Gralinski L.E., Sheahan T.P., Morrison T.E., Menachery V.D., Jensen K., Leist S.R., Whitmore A., Heise M.T., Baric R.S. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio, 2018, vol. 9, no. 5: e01753-18 doi: 10.1128/mBio.01753-18
- Henry B.M., Szergyuk I., de Oliveira M.H.S., Lippi G., Benoit J.L., Vikse J., Benoit S.W. Complement levels at admission as a reflection of Coronavirus Disease 19 (COVID-19) severity state. J. Med. Virol., 2021, vol. 93, no. 9, pp. 5515–5522. doi: 10.1002/jmv.27077
- Java A., Apicelli A.J., Liszewski M.K., Coler-Reilly A., Atkinson J.P., Kim A.H., Kulkarni H.S. The complement system in COVID-19: friend and foe? JCI Insight, 2020, vol. 5, no. 15: e140711. doi: 10.1172/jci.insight.140711
- Jayarangaiah A., Kariyanna P.T., Chen X., Jayarangaiah A., Kumar A. COVID-19-associated coagulopathy: an exacerbated immunothrombosis response. Clin. Appl. Thromb. Hemost., 2020, vol. 26: 1076029620943293. doi: 10.1177/1076029620943293
- Jimenez-Cebrian A.M., Castro-Mendez A., García-Podadera B., Romero-Galisteo R., Medina-Alcántara M., Garcia-Paya I., Páez-Moguer J., Córdoba-Fernández A. Clinical manifestations of COVID-19 in the feet: a review of reviews. J. Clin. Med., 2021, vol. 10, no. 10: 2201. doi: 10.3390/jcm10102201
- Keshavarz F., Ghalamfarsa F., Javdansirat S., Hasanzadeh S., Azizi A., Sabz G., Salehi M., Ghalamfarsa G. Patients with COVID-19 have significantly reduced CH50 activity. Virusdisease, 2021, vol. 32, no. 4, pp. 681–689. doi: 10.1007/s13337-021-00710-6
- Kristensen M.K., Hansen M.B., Madsen M.B., Hansen C.B., Pilely K., Hyldegaard O., Garred P. Complement activation is associated with mortality in patients with necrotizing soft-tissue infections — a prospective observational study. Front. Immunol., 2020, vol. 11: 17. doi: 10.3389/fimmu.2020.00017
- Lippi G., Henry B.M., Hoehn J., Benoit S., Benoit J. Validation of the Corona-Score for rapid identification of SARS-CoV-2 infections in patients seeking emergency department care in the United States. Clin. Chem. Lab. Med., 2020, vol. 8, no. 12, pp. e311–e113. doi: 10.1515/cclm-2020-1121
- McPherson R.A., Pincus M.R. Henry’s clinical diagnosis and management by laboratory methods. Elsevier Health Sciences, 2021. 1618 p. URL: https://www.elsevier.com/books/henrys-clinical-diagnosis-and-management-by-laboratory-methods/mcpherson/ 978-0-323-67320-4 (10.02.2022)
- Melenotte C., Silvin A., Goubet A.G., Lahmar I., Dubuisson A., Zumla A., Raoult D., Merad M., Gachot B., Hénon C., Solary E., Fontenay M., André F., Maeurer M., Ippolito G., Piacentini M., Wang F.S., Ginhoux F., Marabelle A., Kroemer G., Derosa L., Zitvogel L. Immune responses during COVID-19 infection. Oncoimmunology, 2020, vol. 9, no. 1: 1807836. doi: 10.1080/2162402X.2020.1807836
- Qureshi A.I., Baskett W.I., Huang W., Shyu D., Myers D., Lobanova I., Naqvi S.H., Thompson V.S., Shyu C.R. Effect of race and ethnicity on in-hospital mortality in patients with COVID-2019. Ethn. Dis., 2021, vol. 31, no. 3, pp. 389–398. doi: 10.18865/ed.31.3.389
- Raghunandan S., Josephson C.D., Verkerke H., Linam W.M., Ingram T.C., Zerra P.E., Arthur C.M., Stowell S.R., Briones M., Chonat S. Complement inhibition in severe COVID-19 acute respiratory distress syndrome. Front. Pediatr., 2020, vol. 8: 616731. doi: 10.3389/fped.2020.616731
- Shakeri H., Azimian A., Ghasemzadeh-Moghaddam H., Safdari M., Haresabadi M., Daneshmand T., Namdar Ahmadabad H. Evaluation of the relationship between serum levels of zinc, vitamin B12, vitamin D, and clinical outcomes in patients with COVID-19. J. Med. Virol., 2022, vol. 94, no. 1, pp. 141–146. doi: 10.1002/jmv.27277
- Xu W., Sun N.N., Gao H.N., Chen Z.Y., Yang Y., Ju B., Tang L.L. Risk factors analysis of COVID-19 patients with ARDS and prediction based on machine learning. Sci. Rep., 2021, vol. 11, no. 1: 2933. doi: 10.1038/s41598-021-82492-x
- Zhang Z., Li X., Zhang W., Shi Z.-L., Zheng Z., Wang T. Clinical features and treatment of 2019-nCoV pneumonia patients in Wuhan: report of a couple cases. Virol. Sin., 2020, vol. 35, no. 3, pp. 330–336. doi: 10.1007/s12250-020-00203-8
- Zinellu A., Mangoni A.A. Serum complement C3 and C4 and COVID-19 severity and mortality: a systematic review and meta-analysis with meta-regression. Front. Immunol., 2021, vol. 12: 696085. doi: 10.3389/fimmu.2021.696085
Supplementary files
